EGFR and non-small cell lung carcinoma: In eligible patients with metastatic NSCLC possessing specific somatic genomic alterations, such as epidermal growth factor receptor (EGFR) gene mutations, the response to treatment involves corresponding tyrosine kinase inhibitors (TKIs).